摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-碘-2-(4'-甲氧基苄氧基)吡啶 | 1192064-49-5

中文名称
5-碘-2-(4'-甲氧基苄氧基)吡啶
中文别名
——
英文名称
5-iodo-2-((4-methoxybenzyl)oxy)pyridine
英文别名
5-iodo-2-(4'-methoxybenzyloxy)pyridine;2-(4-Methoxybenzyloxy)-5-iodopyridine;5-iodo-2-[(4-methoxyphenyl)methoxy]pyridine
5-碘-2-(4'-甲氧基苄氧基)吡啶化学式
CAS
1192064-49-5
化学式
C13H12INO2
mdl
——
分子量
341.148
InChiKey
VRUVYKSDHWKKHO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
    [FR] COMPOSÉS CYCLOPROPYLIQUES SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
    摘要:
    公式(I)的取代环丙基化合物被披露为治疗或预防2型糖尿病及类似疾病的有效药物。还包括药用可接受的盐和溶剂化合物。这些化合物可作为G蛋白偶联受体GPR-119的激动剂。
    公开号:
    WO2009129036A1
  • 作为产物:
    描述:
    4-甲氧基苄醇2-氟-5-碘吡啶 在 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 5-碘-2-(4'-甲氧基苄氧基)吡啶
    参考文献:
    名称:
    [EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
    [FR] COMPOSÉS CYCLOPROPYLIQUES SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
    摘要:
    公式(I)的取代环丙基化合物被披露为治疗或预防2型糖尿病及类似疾病的有效药物。还包括药用可接受的盐和溶剂化合物。这些化合物可作为G蛋白偶联受体GPR-119的激动剂。
    公开号:
    WO2009129036A1
点击查看最新优质反应信息

文献信息

  • PHENYL BENZYL ETHER DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF
    申请人:ZHANG Zhiyong
    公开号:US20170037008A1
    公开(公告)日:2017-02-09
    Parts of compounds, after being labeled by radionuclide, of the phenyl benzyl ether derivative, are used as Aβ plaque imaging agent. The structural formula of the phenyl benzyl ether derivative is shown by formula (I). The present invention develops a kind of brand new phenyl benzyl ether derivative which has high affinity with Aβ plaques in brains of AD patients. The chemical structure of the phenyl benzyl ether derivative is different from that of compounds disclosed in the prior art and the phenyl benzyl ether derivative belongs to a brand new compound for diagnosing and treating AD. The obtained Aβ plaque imaging agent has the advantages that the in-vivo stability is good, the fat solubility is low, the removal speed for the brain is fast, the problem of removing the radionuclide in vivo does not exist, and the application prospect and the market value are great.
    化合物的部分,在被放射性核素标记后,苄醚生物被用作Aβ斑块成像剂。苄醚生物的结构式如公式(I)所示。本发明开发了一种全新的苄醚生物,其与AD患者大脑中的Aβ斑块具有高亲和力。苄醚生物化学结构与先前公开的化合物不同,且该苄醚生物属于一种全新的用于诊断和治疗AD的化合物。所得的Aβ斑块成像剂具有优点,即体内稳定性好,脂溶性低,对大脑的清除速度快,不存在体内去除放射性核素的问题,且应用前景和市场价值巨大。
  • [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
    申请人:MERCK SHARP & DOHME
    公开号:WO2014120346A1
    公开(公告)日:2014-08-07
    The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.
    本发明提供了一种式(I)的化合物(结构表示),其中R1为H或C1-6烷基,R2为H或C1-6烷基或CH20H,R3为H或C1-6烷基,R4为H或C1-6烷基,但当R1、R2和R3为H时,R4为C1-6烷基,当R1、R2和R4为H时,R3为C1-6烷基,当R1、R3和R4为H时,R2为C1-6烷基或-CH20H,当R2、R3和R4为H时,R1为C1-6烷基;A为1)具有1-3个异原子(N、S和O中独立选择)的9-10成员双环杂环,该9-10成员双环杂环未取代或取代为R5、未取代或取代为R6、未取代或取代为NH2;或2)未取代或取代为R5、未取代或取代为R6、未取代或取代为-CH2NH2的6-9成员单环或双环环系统;B为1)具有1或2个异原子(N、S或O中独立选择)的5-或6成员单环杂环,未取代或在原子上取代为R7、未取代或在原子上取代为R8、未取代或在原子上取代为R9;或2)具有1、2或3个原子的8-或9成员融合双环杂环,在原子上未取代或取代为R7,并在原子上未取代或取代为R8;以及包括一种或多种这些化合物的制药组合物,以及使用这些化合物用于治疗或预防血栓形成的方法。
  • Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
    申请人:Merck Sharp & Dohme Corp.
    公开号:US08343990B2
    公开(公告)日:2013-01-01
    Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
    公开了式(I)的取代环丙基化合物作为治疗或预防2型糖尿病和类似疾病的有用药物。还包括药学上可接受的盐和溶剂。这些化合物作为G蛋白偶联受体GPR-119的激动剂是有用的。
  • Factor IXa Inhibitors
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US20150322056A1
    公开(公告)日:2015-11-12
    The present invention provides a compound of Formula (I) wherein R 1 is H or C 1-6 alkyl, R 2 , is H or C 1-6 alkyl or CH 2 OH, R 3 is H or C 1-6 alkyl, and R 4 is H or C 1-6 alkyl, provided that when R 1 , R 2 , and R 3 are H, R 4 is C 1-6 alkyl, and when R 1 , R 2 , and R 4 are H, then R 3 is C 1-6 alkyl, and when R 1 , R 3 , and R 4 are H, R 2 is C 1-6 alkyl or —CH 2 OH, and when R 2 , R 3 , and R 4 are H, then R 1 is C 1-6 alkyl; A is 1) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and O, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R 5 and unsubstituted or substituted with R 6 and unsubstituted or substituted with NH 2 , or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R 5 , unsubstituted or substituted with R 6 , and unsubstituted or substituted with —CH 2 NH 2 ; and B is 1 ) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or O, which is unsubstituted or substituted on a carbon or nitrogen atom with R 7 , unsubstituted or substituted on a carbon or nitrogen atom with R 8 , and unsubstituted or substituted on a carbon or nitrogen atom with R 9 , or 2 ) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R 7 , and unsubstituted or substituted on a carbon or nitrogen atom with R 8 ; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.
    本发明提供了一种化合物,其化学式为(I),其中R1为H或C1-6烷基,R2为H或C1-6烷基或CH2OH,R3为H或C1-6烷基,R4为H或C1-6烷基,但当R1,R2和R3为H时,R4为C1-6烷基,当R1,R2和R4为H时,R3为C1-6烷基,当R1,R3和R4为H时,R2为C1-6烷基或-CH2OH,当R2,R3和R4为H时,R1为C1-6烷基;A为1)具有1-3个杂原子(N,S和O)的9-10个成员的双环杂环,该9-10个成员的双环杂环未取代或取代为R5,未取代或取代为R6,未取代或取代为NH2,或2)未取代或取代为R5的6-9个成员的单环或双环环系统,未取代或取代为R6,未取代或取代为-CH2NH2;B为1)具有1或2个杂原子(N,S或O)的5或6个成员的单环杂环,未在原子上取代或取代为R7,未在原子上取代或取代为R8,未在原子上取代或取代为R9,或2)具有1,2或3个原子的8或9个成员的融合双环杂环,未在原子上取代或取代为R7,并未在原子上取代或取代为R8;以及包括一种或多种上述化合物的制药组合物,以及使用上述化合物用于治疗或预防血栓形成的方法。
  • SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
    申请人:Wood Harold B
    公开号:US20110028501A1
    公开(公告)日:2011-02-03
    Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
    公开了化合物(I)的替代环丙基化合物,其可用于治疗或预防2型糖尿病和类似情况。还包括药学上可接受的盐和溶剂化物。该化合物可用作G蛋白偶联受体GPR-119的激动剂。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯